A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms AMPLITUDE-O
- Sponsors Sanofi
- 06 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 07 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Apr 2018 According to a Sanofi media release, the trial is planned to initiate in Q2 2018.